MarketPulse

Braftovi

3 articles
BenzingaBenzinga··Vandana Singh

Pfizer's Breast Cancer Drug Hits Survival Goals as Oncology Pipeline Accelerates

Pfizer reports positive Phase 2 data for atirmociclib in metastatic breast cancer, meeting survival endpoints. Company also gains FDA approval for Braftovi in colorectal cancer.
PFEcolorectal cancerFDA approval
BenzingaBenzinga··Vandana Singh

Pfizer's Braftovi Combination Therapy Receives Full FDA Approval for BRAF-Mutated Colorectal Cancer

Pfizer's Braftovi receives full FDA approval for treating BRAF-mutated metastatic colorectal cancer when combined with cetuximab and chemotherapy, based on Phase 3 trial data.
PFEFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Pfizer's Braftovi Regimen Achieves Primary Endpoints in Metastatic Colorectal Cancer Trial

Pfizer's Braftovi regimen met primary endpoints in Phase 3 colorectal cancer trial, showing significant improvements in progression-free survival versus standard chemotherapy in BRAF-mutated patients.
PFEFDLPJPcolorectal cancerBraftovi